The efficacy of panretinal photocoagulation for neovascularization of the iris after central retinal artery obstruction.
Panretinal photocoagulation (PRP) is widely used for a variety of ischemic ocular conditions. In diseases that produce neovascularization of the iris (NVI), such as diabetes mellitus and central retinal vein obstruction, a judiciously timed PRP can reduce the incidence of neovascular glaucoma. Neovascularization of the iris can occur after central retinal artery obstruction (CRAO) as well. In this article, the authors report the outcome of 17 patients who received PRP to treat rubeosis iridis secondary to CRAO. Eleven of the 17 patients (65%) showed regression of NVI after PRP. Although the uncontrolled and retrospective nature of this study precludes drawing definitive conclusions from these data, PRP appears to be effective in reducing the incidence of neovascular glaucoma, if it is delivered before the development of elevated intraocular pressure (IOP). Once neovascular glaucoma occurs, additional modalities appear to be necessary in order to adequately control the elevated IOP.
Duker
J S
JS
Retina Vascular Unit, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA.
Brown
G C
GC
D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D005901:Glaucoma / Q000209:etiology / Q000503:physiopathology; D006801:Humans; D007429:Intraocular Pressure; D007498:Iris / Q000098:blood supply*; D053685:Laser Therapy; D008028:Light Coagulation; D008297:Male; D008875:Middle Aged; D009389:Neovascularization, Pathologic / Q000209:etiology / Q000601:surgery*; D012160:Retina / Q000601:surgery*; D015356:Retinal Artery Occlusion / Q000150:complications*